Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices

Core Viewpoint - Abbott Laboratories (NYSE: ABT) has been assigned a "Strong Buy" rating due to its robust growth in the medical device and pharmaceutical markets, leading to significant stock price outperformance compared to the overall market index [1]. Company Performance - Since the "Strong Buy" rating was assigned in October 2024, Abbott's stock price has significantly outperformed the overall market index, indicating strong investor confidence and market performance [1]. Market Position - Abbott Laboratories is experiencing strong growth in both the medical device and pharmaceutical sectors, which are key drivers of its stock performance and overall business success [1].